UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2388-2395

2013

Volltextzugriff (PDF)

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2396-2403

2013

Volltextzugriff (PDF)

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2413-2420

2013

Volltextzugriff (PDF)

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

The cancer journal (Sudbury, Mass.), 2010-07, Vol.16 (4), p.399-403

2010

Volltextzugriff (PDF)

GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development

Vaccine, 2007-09, Vol.25, p.B61-B71

2007

Volltextzugriff (PDF)

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet oncology, 2018-07, Vol.19 (7), p.916-929

2018

Volltextzugriff (PDF)

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

Journal of thoracic oncology, 2016-12, Vol.11 (12), p.2208-2217

2016

Volltextzugriff (PDF)

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer

Clinical cancer research, 2020-04, Vol.26 (7), p.1725-1735

2020

Volltextzugriff (PDF)

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer

Journal of thoracic oncology, 2015-10, Vol.10 (10), p.1458-1467

2015

Volltextzugriff (PDF)

Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease

Expert opinion on biological therapy, 2008-07, Vol.8 (7), p.951-968

2008

Volltextzugriff (PDF)

MAGE-A3-specific anticancer immunotherapy in the clinical practice

Oncoimmunology, 2013-10, Vol.2 (10), p.e25995-e25995

2013

Volltextzugriff (PDF)

The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients

Lung cancer (Amsterdam, Netherlands), 2016-11, Vol.101, p.137-144

2016

Volltextzugriff (PDF)

Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy

Journal of immunotherapy (1997), 2013-02, Vol.36 (2), p.79-81

2013

Volltextzugriff (PDF)

Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells

Journal of clinical oncology, 2005-12, Vol.23 (35), p.9008-9021

2005

Volltextzugriff (PDF)

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma

International journal of cancer, 2005-11, Vol.117 (4), p.596-604

2005

Volltextzugriff (PDF)

Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma

Journal of immunotherapy, 2007-11, Vol.30 (8), p.847-854

2007

Volltextzugriff (PDF)

New tumor antigens recognized by T cells

Current opinion in immunology, 1995-10, Vol.7 (5), p.674-681

1995

Volltextzugriff (PDF)

Prognostic value of MAGE-A3 and PRAME gene expression in non-small-cell lung cancer (NSCLC)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7056-7056

2012

Volltextzugriff (PDF)

Analysis of Spontaneous Vs. Vaccine-Induced Antibody Responses Against Cancer-Testis Antigen MAGE-A3 in Cancer Patients

Blood, 2011-11, Vol.118 (21), p.5087-5087

2011

Volltextzugriff (PDF)

MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7013-7013

2012

Volltextzugriff (PDF)

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene

The Journal of experimental medicine, 1996-03, Vol.183 (3), p.1173-1183

1996

Volltextzugriff (PDF)

Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

Immunological reviews, 1995-06, Vol.145 (1), p.229-250

1995

Volltextzugriff (PDF)

A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes

European journal of immunology, 1996-01, Vol.26 (1), p.224-230

1996

Volltextzugriff (PDF)

Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus

The Journal of immunology (1950), 1996-11, Vol.157 (9), p.4079-4086

1996

Volltextzugriff (PDF)

B1-05: Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S334-S335

2007

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Humans
(29)
Life Sciences & Biomedicine
(28)
Oncology
(18)
Melanoma - Immunology
(15)
Female
(14)
Antigens, Neoplasm - Immunology
(12)
Immunology
(12)
Male
(12)
T-Lymphocytes, Cytotoxic - Immunology
(12)
Biological And Medical Sciences
(11)
Immunotherapy
(11)
Medical Sciences
(11)
Adult
(10)
Tumors
(10)
Aged
(9)
Cancer Vaccines - Therapeutic Use
(9)
Middle Aged
(9)
Amino Acid Sequence
(8)
Animals
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer

Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease

MAGE-A3-specific anticancer immunotherapy in the clinical practice

The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients

Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy

Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma

Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma

New tumor antigens recognized by T cells

Prognostic value of MAGE-A3 and PRAME gene expression in non-small-cell lung cancer (NSCLC)

Analysis of Spontaneous Vs. Vaccine-Induced Antibody Responses Against Cancer-Testis Antigen MAGE-A3 in Cancer Patients

MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene

Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes

Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus

B1-05: Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study

Suchergebnisse filtern